GVM±R in Patients With Relapsed or Refractory Aggressive NHL
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, dose-escalation clinical study to evaluate the safety and efficacy of
GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).